Cellular Intelligence's STEM-PD data, presented at ISSCR and in Nature Medicine, shows safety signals and reduced medication use in Parkinson's patients ahead of a planned Phase 2.
MONTREAL — After Novo Nordisk closed its cell therapy unit, Cellular Intelligence contracted neurologist and drug developer Nuno Mendonça to conduct due diligence on the Danish …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
La farmacéutica danesa ha transferido la investigación a Cellular Intelligence con el objetivo de que esta pueda acelerar su…
The partnership will enable Novo to better use AI to analyze complex datasets, and identify promising new drugs.
Novo Nordisk's global research head Jacob Sten Petersen discusses post-reorganization R&D strategy, pipeline diversification…
NeuroScientific Biopharmaceuticals has reported an 80% response rate from five Crohn’s disease patients treated with its…
Stay up to date with notifications from The IndependentNotifications can be managed in browser preferences.Jump to contentThank…
Due studi clinici sul trapianto di neuroni da staminali nel Parkinson: sicurezza confermata dopo 12 mesi di osservazione.
